The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Non-Alcoholic Steatohepatitis (NASH) Drugs-Global Market Insights and Sales Trends 2024
Synopsis
Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.
The global Non-Alcoholic Steatohepatitis (NASH) Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Non-Alcoholic Steatohepatitis (NASH) Drugs in various end use industries. The expanding demands from the Hospital Pharmacy, Online Provider and Retail Pharmacy,, are propelling Non-Alcoholic Steatohepatitis (NASH) Drugs market. Vitamin E & Pioglitazone, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Obeticholic Acid (OCA) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Non-Alcoholic Steatohepatitis (NASH) Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Non-Alcoholic Steatohepatitis (NASH) Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Non-Alcoholic Steatohepatitis (NASH) Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Non-Alcoholic Steatohepatitis (NASH) Drugs covered in this report include AstraZeneca, Conatus Pharmaceuticals, Enzo Biochem, Galmed Pharmaceuticals, Genfit, Gilead, Horizon Pharma, Immuron and Intercept Pharmaceuticals, etc.
The global Non-Alcoholic Steatohepatitis (NASH) Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Conatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals
Novo Nordisk
Global Non-Alcoholic Steatohepatitis (NASH) Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Non-Alcoholic Steatohepatitis (NASH) Drugs market, Segment by Type:
Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Elafibranor
Selonsertib & Cenicriviroc
Global Non-Alcoholic Steatohepatitis (NASH) Drugs market, by Application
Hospital Pharmacy
Online Provider
Retail Pharmacy
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Non-Alcoholic Steatohepatitis (NASH) Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.
The global Non-Alcoholic Steatohepatitis (NASH) Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Non-Alcoholic Steatohepatitis (NASH) Drugs in various end use industries. The expanding demands from the Hospital Pharmacy, Online Provider and Retail Pharmacy,, are propelling Non-Alcoholic Steatohepatitis (NASH) Drugs market. Vitamin E & Pioglitazone, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Obeticholic Acid (OCA) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Non-Alcoholic Steatohepatitis (NASH) Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Non-Alcoholic Steatohepatitis (NASH) Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Non-Alcoholic Steatohepatitis (NASH) Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Non-Alcoholic Steatohepatitis (NASH) Drugs covered in this report include AstraZeneca, Conatus Pharmaceuticals, Enzo Biochem, Galmed Pharmaceuticals, Genfit, Gilead, Horizon Pharma, Immuron and Intercept Pharmaceuticals, etc.
The global Non-Alcoholic Steatohepatitis (NASH) Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Conatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals
Novo Nordisk
Global Non-Alcoholic Steatohepatitis (NASH) Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Non-Alcoholic Steatohepatitis (NASH) Drugs market, Segment by Type:
Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Elafibranor
Selonsertib & Cenicriviroc
Global Non-Alcoholic Steatohepatitis (NASH) Drugs market, by Application
Hospital Pharmacy
Online Provider
Retail Pharmacy
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Non-Alcoholic Steatohepatitis (NASH) Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Non-Alcoholic Steatohepatitis (NASH) Drugs
1.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Overview
1.1.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Product Scope
1.1.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Status and Outlook
1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2018-2029)
1.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Region (2018-2023)
1.5 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2029)
1.6.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2029)
1.6.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2029)
1.6.4 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2018-2029)
2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market by Type
2.1 Introduction
2.1.1 Vitamin E & Pioglitazone
2.1.2 Obeticholic Acid (OCA)
2.1.3 Elafibranor
2.1.4 Selonsertib & Cenicriviroc
2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Breakdown by Type (2018-2029)
3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacy
3.1.2 Online Provider
3.1.3 Retail Pharmacy
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Breakdown by Application (2018-2029)
4 Non-Alcoholic Steatohepatitis (NASH) Drugs Competition Analysis by Players
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2022)
4.3 Date of Key Players Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
4.4 Global Top Players Non-Alcoholic Steatohepatitis (NASH) Drugs Headquarters and Area Served
4.5 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 AstraZeneca
5.1.1 AstraZeneca Profile
5.1.2 AstraZeneca Main Business
5.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Products, Services and Solutions
5.1.4 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 AstraZeneca Recent Developments
5.2 Conatus Pharmaceuticals
5.2.1 Conatus Pharmaceuticals Profile
5.2.2 Conatus Pharmaceuticals Main Business
5.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Products, Services and Solutions
5.2.4 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Conatus Pharmaceuticals Recent Developments
5.3 Enzo Biochem
5.3.1 Enzo Biochem Profile
5.3.2 Enzo Biochem Main Business
5.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Products, Services and Solutions
5.3.4 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Galmed Pharmaceuticals Recent Developments
5.4 Galmed Pharmaceuticals
5.4.1 Galmed Pharmaceuticals Profile
5.4.2 Galmed Pharmaceuticals Main Business
5.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Products, Services and Solutions
5.4.4 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Galmed Pharmaceuticals Recent Developments
5.5 Genfit
5.5.1 Genfit Profile
5.5.2 Genfit Main Business
5.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Products, Services and Solutions
5.5.4 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Genfit Recent Developments
5.6 Gilead
5.6.1 Gilead Profile
5.6.2 Gilead Main Business
5.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Products, Services and Solutions
5.6.4 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Gilead Recent Developments
5.7 Horizon Pharma
5.7.1 Horizon Pharma Profile
5.7.2 Horizon Pharma Main Business
5.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Products, Services and Solutions
5.7.4 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Horizon Pharma Recent Developments
5.8 Immuron
5.8.1 Immuron Profile
5.8.2 Immuron Main Business
5.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Products, Services and Solutions
5.8.4 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Immuron Recent Developments
5.9 Intercept Pharmaceuticals
5.9.1 Intercept Pharmaceuticals Profile
5.9.2 Intercept Pharmaceuticals Main Business
5.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Products, Services and Solutions
5.9.4 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Intercept Pharmaceuticals Recent Developments
5.10 Novo Nordisk
5.10.1 Novo Nordisk Profile
5.10.2 Novo Nordisk Main Business
5.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Products, Services and Solutions
5.10.4 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Novo Nordisk Recent Developments
6 North America
6.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Dynamics
11.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Trends
11.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
11.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
11.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
